OPN Polymorphism Is Related to the Chemotherapy Response and Prognosis in Advanced NSCLC

Table 2

The genotype frequencies for HIF-1𝛼 polymorphisms between well responders and poor responders to platinum-based chemotherapy.

OPN genotype	Well responders; 𝑁=167	%	Poor responders; 𝑁=330	%	adjusted OR	95% CI		Adjusted; 𝑃
	𝑁	%	𝑁	%
−443C>T
CC	29	17.37%	119	36.06%	1.00
CT	70	41.92%	148	44.85%	1.94	1.18	3.19	0.008
TT	68	40.72%	63	19.09%	4.43	2.60	7.53	<0.001
C	128	38.32%	543	51.03%	1.00
T	206	61.68%	521	48.97%	1.68	1.30	2.16	<0.001
−156/G>GG
GG	44	26.35%	89	26.97%	1.00
GGG	80	47.90%	143	43.33%	1.13	0.72	1.78	0.593
GGGG	43	25.75%	98	29.70%	0.89	0.53	1.48	0.646
G	168	50.30%	543	51.03%	1.00
GG	166	49.70%	521	48.97%	1.03	0.81	1.32	0.815
−66T>G
TT	48	28.74%	98	29.70%	1.00
TG	71	42.51%	142	43.03%	1.02	0.65	1.60	0.928
GG	48	28.74%	90	27.27%	1.09	0.67	1.78	0.734
T	167	50.00%	543	51.03%	1.00
G	167	50.00%	521	48.97%	1.04	0.82	1.33	0.742